Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study

Federica Sora', Roberto Latagliata, Dario Ferrero, Alessandra Iurlo, Francesco Cavazzini, Fausto Castagnetti, Elisabetta Abruzzese, Carmen Fava, Massimo Breccia, Mario Annunziata, Fabio Stagno, Mario Tiribelli, Gianni Binotto, Giovanna Mansueto, Antonella Gozzini, Sabina Russo, Laura Cavalli, Enrico Montefusco, Gabriele Gugliotta, Michele CedroneAntonella Russo Rossi, Paolo Avanzini, Patrizia Pregno, Endri Mauro, Antonio Spadea, Francesca Celesti, Gianfranco Giglio, Alessandro Isidori, Monica Crugnola, Elisabetta Calistri, Ada D'Addosio, Giovanna Rege-Cambrin, Luigiana Luciano, Giuliana Alimena

Risultato della ricerca: Contributo in rivistaArticolo in rivista

27 Citazioni (Scopus)

Abstract

A large number of chronic myeloid leukemia (CML) patients are treated with imatinib mesylate outside of clinical trials, which may not be representative of common clinical practice. The age of CML patients enrolled within controlled clinical studies is lower with respect to patients included in population-based registries.
Lingua originaleEnglish
pagine (da-a)629-637
Numero di pagine9
RivistaDRUGS & AGING
Volume30
DOI
Stato di pubblicazionePubblicato - 2013

Keywords

  • Aged
  • Aged, 80 and over
  • Aging
  • Antineoplastic Agents
  • Benzamides
  • Cohort Studies
  • Comorbidity
  • Dose-Response Relationship, Drug
  • Drug Monitoring
  • Female
  • Follow-Up Studies
  • Humans
  • Italy
  • Leukemia, Myeloid, Chronic-Phase
  • Male
  • Neoplasm Grading
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Remission Induction
  • Retrospective Studies
  • Survival Analysis

Fingerprint Entra nei temi di ricerca di 'Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study'. Insieme formano una fingerprint unica.

Cita questo